Akari Therapeutics
AKTX
13 hedge funds and large institutions have $63.5M invested in Akari Therapeutics in 2015 Q3 according to their latest regulatory filings, with 12 funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
35,712% more capital invested
Capital invested by funds: $177K → $63.5M (+$63.3M)
1,100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 1
550% more funds holding
Funds holding: 2 → 13 (+11)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$17M |
| 2 |
VM
VHCP Management
New York
|
+$7.81M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$5.86M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$3.9M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$1.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DM
1
Deerfield Management
New York
| $27.6M | +$17M | +1,438 | New |
|
|
VM
2
VHCP Management
New York
| $12.7M | +$7.81M | +660 | New |
|
|
BBA
3
Baker Bros. Advisors
New York
| $9.5M | +$5.86M | +495 | New |
|
|
RCM
4
RA Capital Management
Boston,
Massachusetts
| $6.33M | +$3.9M | +330 | New |
|
|
EC
5
EcoR1 Capital
San Francisco,
California
| $2.42M | +$1.49M | +126 | New |
|
6
Millennium Management
New York
| $1.49M | +$911K | +77 | New |
|
|
TI
7
Turner Investments
Berwyn,
Pennsylvania
| $1M | +$615K | +52 | New |
|
|
CAM
8
Cormorant Asset Management
Boston,
Massachusetts
| $687K | – | – | – |
|
|
NMC
9
NEA Management Company
Timonium,
Maryland
| $645K | +$402K | +34 | New |
|
|
DCM
10
DAFNA Capital Management
Los Angeles,
California
| $633K | +$390K | +33 | New |
|
|
GTC
11
Ghost Tree Capital
New York
| $488K | +$296K | +25 | New |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| $23K | +$11.8K | +1 | New |
|
13
UBS Group
Zurich,
Switzerland
| $21K | +$11.8K | +1 | New |
|
|
AIG
14
American International Group
New York
| $1K | – | – | – |
|
|
15
Citadel Advisors
Miami,
Florida
| – | -$9K | -2 | Closed |
|
AKTX Hedge Fund Activity: Q3 2015 in Review
13 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q3 2015, worth a combined $63.5M — up 35,712% from $177K a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new AKTX positions and 1 closed out — a net gain of 11 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $17M. The largest seller was Citadel Advisors, exiting entirely with an estimated $9K sold.
- 13 institutional investors held Akari Therapeutics (AKTX) as of Q3 2015, up from 2 in Q2 2015.
- Funds reported $63.5M of Akari Therapeutics stock for Q3 2015, up 35,712% quarter-over-quarter.
- 12 funds opened new Akari Therapeutics positions in Q3 2015 and 1 closed out, a net change of +11 holders.
- The largest Akari Therapeutics buyer in Q3 2015 was Deerfield Management, an estimated $17M added.
- The largest Akari Therapeutics seller in Q3 2015 was Citadel Advisors, an estimated $9K sold.
Based on aggregated 13F filings for Q3 2015.